Congenital diaphragmatic hernia (CDH) occurs in 1 of 4,000-5,000 live births. Despite advances in the care of these infants, pulmonary hypoplasia and resulting pulmonary hypertension (PH) carry significant morbidity and mortality. Thus, additional therapeutic strategies are needed. The use of continuous treprostinil for chronic pediatric pulmonary hypertensive disorders is increasing. However, its use for acute therapy is limited. We describe two 6-week-old infants with CDH and severe pulmonary hypertension treated with treprostinil. Rapid and dramatic clinical and hemodynamic improvement occurred in both cases. Both infants were weaned off the drug, representing the first reports of successful short-term treprostinil use in neonates with CDH. Case 1 was a female infant born at 37 weeks' gestation, after a pregnancy complicated by late prenatal care, with left-sided, liver-up CDH. Patient underwent an uncomplicated hernia repair of DOL 3. Cardiac echo demonstrated suprasystemic RVp, requiring intubation with iNO. Patient was treated with PGE1 to maintain ductal patency with improvement in respiratory function and echo estimate of RVp. However, at 4 weeks of age, the child's status deteriorated with a PH crises. At 6 weeks of age, cardiac catheterization measured suprasystemic PAp with severely elevated PVR of 13.5 Wood units; minimal PVR was 9.9 with vasodilators. Continuous IV epoprostenol was started, with transition to IV treprostinil after 48 hours. The dose was titrated over the next 4 weeks to a peak dose of 48 ng/kg/min, with minimal side effects. This resulted in significant clinical improvement and a decrease in BNP from 4,080 to 25 pg/mL. At 10 weeks, the patient was weaned off treprostinil, and treprostinil therapy was discontinued 30 days later. The infant was discharged at 5 months of age on bosentan and 0.5 LPM NC oxygen. Repeat cardiac catheterization at 7 months demonstrated a PVR of 3.7 Wood units. At 1-year follow-up, the infant was weaned off both oxygen and bosentan and continues to grow and develop well, with normal pulmonary pressures estimated by echo. Case 2 was a full-term female infant with prenatally diagnosed severe, left-sided, liver-up CDH. Echo on DOL 1 demonstrated suprasystemic RVp and decreased function. Patient underwent hernia repair with internal oblique muscle flap on DOL 2. Infant was supported on HFOV, FiO 2 of 100%, 20-ppm iNO, and
PGE. Patient was extubated to NCPAP at 2 weeks but continued on iNO, PGE, and milrinone. Repeat echo at 6 weeks was unchanged, with suprasystemic RVp and decreased function. At 6.5 weeks of age, cardiac catheterization measured systemic pulmonary pressures at baseline, with elevated PVR of 7.1 Wood units; minimal PVR was 5.8 with vasodilators. Continuous SC treprostinil was initiated and titrated up over the next 5 weeks to a peak dose of 52 ng/kg/min. This resulted in significant clinical improvement, including a successful weaning off PGE, milrinone, and iNO within 2 weeks. BNP decreased from 143 to 5 pg/mL. Patient was discharged home at 3.5 months of age on 0.5 L/min O 2 and SC treprostinil. Bosentan was initiated at 6 months in anticipation of treprostinil weaning, and repeat cardiac catheterization at 8 months of age on room air demonstrated normal pulmonary pressures and a PVR of 4.3 Wood units. Patient was successfully weaned off treprostinil over the next 4 weeks and is maintained on bosentan, with excellent growth and development and normal pulmonary pressures estimated by echo. In conclusion, these 2 cases demonstrate the benefit of short-term treprostinil use initiated at 6-8 weeks of age in neonates with severe PH following CDH repair. These cases are consistent with our prior report demonstrating pulmonary vascular reactivity in infants with CDH at 2-3 months of age. Further, the successful use of SC treprostinil improves the safety of administration of prostacyclins in this vulnerable population, eliminating the need for a central line and its associated risks and allowing for outpatient therapy in a young infant.
Initial clinical experience with oral treprostinil (UT-15C) in pediatric pulmonary hypertension at a single center BA Coleman, M Calderbank, DD Ivy Department of Pediatric Cardiology, Children's Hospital Colorado, University of Colorado Denver, Aurora, Colorado, USA
The specific aims of this retrospective study were to evaluate (1) dosing and tolerance of oral treprostinil in patients 10-20 years old with weight > 25 kg and (2) clinical stability of pulmonary arterial hypertension (PAH) with transition from parenteral/inhaled treprostinil to or add-on initiation of oral treprostinil. PAH is an important cause of morbidity and mortality in pediatric patients. Advances in understanding the pathobiology of PAH have led to novel therapies. Administration of drug therapies targeting the prostacyclin pathway have historically been complex, requiring an indwelling central venous line, with risk of line infection and dislodgement, or placement of a subcutaneous catheter, complicated by site pain and skin infections. Inhaled therapies require frequent dosing, with compliance issues. These factors have increased the risk for delivery of prostacyclin therapy as well as affected patients' quality of life. In December 2013, oral treprostinil (UT-15C) received FDA approval as the first orally administered prostacyclin for any disease. We conducted a retrospective chart review of 8 patient initiations (5 IPAH, 3 CHD). All patients were WSPH group I. Patient selection was based on clinician assessment of clinical stability, including WHO FC II-III, 6MWD > 425 m, absence of RV failure, and IV/SQ dose < 125 ng/kg/min. All patients were on background ERA, PDE5i, and/or CCB therapy. Seven patients transitioned from prostacyclin (5 inhaled treprostinil, 1 inhaled iloprost, 1 SQ treprostinil). In 1 patient, UT-15C was added to background therapy. Seven transitions were successful and did not require change in therapy. In 1 patient admitted for SQ-to-oral transition, clinical deterioration occurred during downtitration of SQ therapy and uptitration of UT-15C, resulting in immediate reinitiation of SQ therapy. One patient discontinued UT-15C after 4 months because of recurrent migraines. Six-minute walk distance improved in 4 of the 5 patients with repeat measurement. Most common adverse events Pulm Circ 2015;5(4):744-750. DOI: 10.1086/684479. (AEs) included headaches (88%), flushing (88%), nausea and vomiting (75%), migraines (25%), heartburn (25%), anorexia (25%), and diarrhea (25%). Most AEs were moderate and transient and improved with slowing uptitration. In conclusion, oral treprostinil was well tolerated in some pediatric PAH patients, with clinical stability or improvement in 75%. Twenty-five percent of patients discontinued UT-15C because of worsening PAH and migraines.
Increased nutritional intake is protective against oxygen-induced right ventricular hypertrophy in neonatal rats SM White, S Wedgwood, RH Steinhorn Division of Neonatology, Department of Pediatrics, UC Davis Children's Hospital, University of California at Davis Medical Center, Sacramento, California, USA Between 25% and 35% of premature infants with moderate-to-severe bronchopulmonary dysplasia (BPD) develop pulmonary hypertension (PH) and right ventricular hypertrophy (RVH), although the underlying mechanisms remain poorly understood. Recent studies identified low birth weight as a predictor of PH in premature infants with BPD, but the potential benefits of nutritional enhancement after birth are unknown. We hypothesized that increased postnatal nutritional intake attenuates oxygen-induced PH in neonatal rats. Sprague-Dawley rat pups were randomized at birth to litters maintained in room air (Air) or 75% oxygen (Hyperoxia), together with litters of normal (10 pups) or enhanced (5 pups) nutritional intake. At day 14, pups were euthanized, and hearts and lungs were isolated for lung inflations or tissue analysis. Inflated lungs were fixed, sectioned, and stained for von Willebrand factor. RVH was determined by calculating the Fulton index (the ratio of the weight of the right ventricle divided by the weight of the left ventricle plus septum). Lung tissue was homogenized and lung protein analyzed by Western blotting. At day 14, Air-Normal, Hyperoxia-Normal, and Hyperoxia-Enhanced pups weighed 29 ± 0.7, 28 ± 0.3, and 34 ± 1.7 g, respectively. In Hyperoxia-Normal versus Air-Normal pups, hyperoxia significantly increased the Fulton index (0.19 ± 0.01 vs. 0.32 ± 0.02), reduced vascular density (27.5 ± 1.6 vs. 14.7 ± 0.7 vessels), increased medial-wall thickness (31.2 ± 1.2 vs. 36.4 ± 1.8), decreased angiogenesis as detected by decreased VEGFR2 protein (63% ± 10% reduction), and increased oxidative stress as detected by increased 3-nitrotyrosine protein (259% ± 82%). Nutritional enhancement in Hyperoxia pups significantly decreased the Fulton index to 0.24 ± 0.02, increased vessel density by 34% ± 8%, normalized VEGFR2 (308% ± 54%), and reduced 3-nitrotyrosine by 32% ± 18% (all compared to Hyperoxia-Normal intake pups). Nutritional enhancement had no effect on medial-wall thickness (36.3 ± 1.9). In conclusion, enhanced postnatal nutritional intake partially protects against oxygen-induced PH in neonatal rats. This may be due in part to increased angiogenesis via VEGF signaling, in addition to decreased oxidative stress. Further studies are warranted to identify the underlying mechanisms. Nutritional intervention may be effective in attenuating the risk of developing PH in premature infants with BPD. High inspired oxygen concentration (FiO 2 ), with or without inhaled nitric oxide (iNO), is administered to test pulmonary vasoreactivity in children with pulmonary hypertension (PH). Oxygen consumption (VO 2 ) cannot be measured accurately in FiO 2 > 0.8 in routine clinical practice. It is assumed that VO 2 is unchanged during hyperoxia. Our preliminary data suggests that VO 2 changes substantially in hyperoxia. Carbon dioxide production (VCO 2 ) is easy to measure in hyperoxia. We sought to calculate cardiac output (CO) by using (VCO 2 ) instead of VO 2 during hyperoxia and compared the results with CO measured by thermodilution (TD) in children with PH. We measured the VO 2 and VCO 2 by mass spectrometry (AMIS 2000, Innovision, Odense, Denmark) during cardiac catheterization. CO was calculated using TD, the Fick equation (VO 2 ), and a CO 2 -modified Fick equation (VCO 2 ) in room air (RA) and hyperoxia (FiO 2 > 0.85 with or without iNO). We studied prospectively 7 patients without shunts (median age: 1.2 years [interquartile range (IQR): 0.9-8.7], median weight: 7.2 kg [IQR: 5.1-27], median BSA: 0.6 [IQR 0.3-1.0]). Mean CO measured in room air was 2.7 ± 0.96 (TD), 2.2 ± 1.2 (Fick), and 2.1 ± 0.9 L/min (CO 2 -modified Fick). The correlation between CO measured by Fick and that by CO 2 -modified Fick was significant (coefficient: 0.86, P = 0.013) in RA. In hyperoxia, the mean CO measured by TD was 2.2 ± 1; that by CO 2 -modified Fick was 2.6 ± 1.1 L/min and correlated well (coefficient: 0.9, P = 0.036). In conclusion, in patients without intracardiac shunts, CO calculated by substituting CO 2 in the Fick equation correlated well with CO measured by TD in room air and in hyperoxia. If VCO 2 is measured, solving the Fick equation for CO 2 may be a practical alternative to calculate CO in hyperoxia in situations where TD is unavailable or inaccurate.
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Mesenchymal stem cell administration in an infant with severe bronchopulmonary dysplasia and pulmonary hypertension: case report There is a lack of effective preventative or therapeutic strategy for bronchopulmonary displasia (BPD). Mesenchymal stem cell (MSC) administration has shown the ability to prevent/revert the histological lesions in rodent hyperoxia models of BPD, but only one clinical trial has explored the safety of MSCs in preterm babies. Our objective was to report our experience with MSC compassionate treatment in an infant with severe BPD. We describe the clinical course, temporal profile of serum cytokines and growth factors, and results of histology and molecular cytogenetic study of the lung. The patient was a female baby born at 24+3 weeks GA, birth weight 695 g (p50), by urgent Caesarean section. The clinical course was unfavorable, and at 5 months of age she was still on mechanical ventilation with 100% oxygen and had severe pulmonary hypertension and CT scan evidence of severe parenchymal disease. The parents were offered and agreed to off-label treatment with heterologous, human male bone marrow-derived MSCs. Increasing weekly doses were administered intravenously up to 5 doses. Before each MSC dose, serum expression of VEGF, PDGF, FGF, TGF-β, MEOX2, SHH, GREMLIN-1; adhesion molecules (VCAM-1, ICAM-1); nitric oxide pathway (eNOS, sGC, PDE1, PDE5, PKG); surfactant proteins (SP-A, SP-B, SP-C, SP-D); and inflammatory markers (IL-1β, IL-6, IL-8, IL-10, TGF-β, TNF-α, GM-CSF) were analyzed. The girl died 6 weeks after start of therapy, without showing either clear improvement in the respiratory function or side effects of the MSC administration. Molecular cytogenetic study of the lung ruled out engraftment of the MSCs. In conclusion, the observed profile of inflammation markers, short-term safety, and absence of engraftment follow-ing MSC administration could serve in the design of future trials on MSC therapy for BPD. Prostacyclins are used to treat PH, and subcutaneous (SQ) treprostinil use has been described in infants with bronchopulmonary dysplasia. We hypothesized that SQ treprostinil may be effective for use in infants with CDH and severe PH. We describe 4 infants at our hospital between 2012 and 2014 who underwent CDH repair and had evidence of PH and heart failure on echocardiogram. SQ treprostinil was initiated in consultation with the surgery team as an option instead of progression to ECMO. In conclusion, SQ treprostinil was generally well tolerated, and in all cases, there was no progression to ECMO after initiation. In the future, initiation could be considered earlier.
Use of serial echocardiography to screen for pulmonary hypertension in premature infants with bronchopulmonary dysplasia Oral treprostinil was recently approved for the treatment of pulmonary arterial hypertension (PAH). The absorption of treprostinil is affected by food. The medication may also cause gastrointestinal symptoms that may influence appetite. The influence of oral therapy on growth is not known. We sought to determine whether patients experienced a change in body mass index (BMI) during the transition from inhaled to oral treprostinil. Six patients with PAH and a median age of 15 years (7-21 years) were transitioned from inhaled to oral therapy after August 2014. On average, patients were transitioned from an inhaled dose of 172 μg/day to an oral dose of 0.83 mg/ day. There was no overlap in treatment with the inhaled and oral therapies. We tracked BMI from 3-15 months before the onset to 1-7 months after the onset of oral therapy. The dose was increased to 3.5 mg/day after 1-7 months of oral therapy. All patients made the transition without reverting to inhaled therapy or starting parenteral therapy. BMI measurements were 19.3 ± 2.2 kg/m 2 3-15 months before, 20.1 ± 2.3 kg/m 2 at the onset, and 20.1 ± 2.4 kg/m 2 1-7 months after the transition to oral therapy. BMI decreased more than 2 kg/m 2 in 1 patient and increased more than 2 kg/m 2 in 1 patient. Both patients had similar trends before the onset of oral therapy. Three patients experienced nausea, diarrhea, or loss of appetite. Sudden death occurred in the patient whose BMI decreased more than 2 kg/m 2 . All patients were pleased with the convenience of oral therapy. In conclusion, collectively, our patients maintained a stable BMI during the early transition from inhaled to oral treprostinil. A substantial decrease in BMI may result from an adverse effect of treatment or progression of disease during therapy. Transthoracic echocardiography is the most common noninvasive modality used to assess for pulmonary hypertension (PH) in the pediatric population. This study aimed to compare plasma N-terminal pro-B-type natriuretic peptide (proBNP) levels to echocardiographic pulmonary artery (PA) pressure estimates in infants and young children with suspected PH. This is a retrospective study of patients ≤3 years of age with clinically suspected PH for whom proBNP levels had been obtained. Echocardiograms performed within 4 days of each proBNP measurement were interpreted by a blinded reviewer and were grouped according to PA pressure as estimated by tricuspid regurgitation peak systolic velocity or interventricular septal configuration (group 1: less than half systemic, group 2: half systemic to systemic, group 3: suprasystemic). Forty-four subjects (20 male) with a total of 76 paired proBNP values and echocardiograms were identified. Primary diagnoses included prematurity/bronchopulmonary dysplasia (n = 31), persistent pulmonary hypertension of the newborn (n = 7), congenital diaphragmatic hernia (n = 1), and others (n = 5). The number of proBNP values obtained in each group were 32 for group 1, 22 for group 2, and 22 for group 3. Median proBNP was 689 pg/mL (range: 66-6,767) in group 1, 2,055 pg/mL (394-26,290) in group 2, and 6,024 pg/mL (506-36,524) in group 3. Group 3 had significantly higher proBNP levels than groups 1 (P < 0.001) and 2 (P = 0.006), and group 2 had significantly higher proBNP levels than group 1 (P < 0.001). A proBNP value less than 568 pg/mL identifies subjects with less than half systemic-level PA pressure estimates (sensitivity: 91%, specificity: 44%). Increasing the cutoff value to 935 pg/mL changes sensitivity and specificity to 86% and 75%, respectively. In conclusion, higher proBNP levels are associated with higher echocardiographic estimates of PA pressure in infants and young children with suspected PH. ProBNP may serve as a useful adjunctive screening tool in this population. Sildenafil is a phosphodiesterase-5 inhibitor used off-label in pediatric pulmonary hypertension (PH). In critically ill infants with suboptimal absorption of enteral medications or intolerance of the acute systemic vasodilatory effects of bolus intravenous (IV) sildenafil, a continuous infusion is a possible alternative. We describe a single-center experience with continuous IV sildenafil in infants with PH. This is a retrospective study of infants less than 6 months old who received continuous IV sildenafil for PH from 2011 to 2015. Twenty subjects (9 male) were identified. Primary diagnoses included meconium aspiration (n = 11), prematurity/bronchopulmonary dysplasia (n = 3), congenital diaphragmatic hernia (n = 2), congenital heart disease (n = 2; transitional atrioventricular canal defect and aortic coarctation), omphalocele with pulmonary hypoplasia (n = 1), and viral bronchiolitis (n = 1). Median age at diagnosis was 0 days (range: 0-171). Eleven subjects required extracorporeal membrane oxygenation (ECMO); 1 started sildenafil before cannulation, 7 during ECMO support, and 3 after decannulation. Median dose was 1.6 mg/kg/day (1.2-1.6), and 6 subjects received a 0.4-mg/kg IV loading dose. Median length of infusion was 5 days (1-92). Side effects included hypotension (n = 4, none of whom had received a loading dose) and hypoxia from ventilation-perfusion mismatch (n = 1). Two of these required discontinuation. All subjects were concomitantly treated with inhaled nitric oxide; some also received inhaled iloprost (n = 5) and/or IV epoprostenol (n = 4). Five subjects died during hospitalization. After recovery, 11 survivors were transitioned to oral sildenafil and 2 stopped treatment. There were no late deaths at a median follow-up duration of 14.9 months (0.2-43.1). In conclusion, continuous IV sildenafil is a feasible alternative to enteral or intermittent IV dosing in the critically ill infant with PH. Further studies of safety and efficacy are warranted. As with all systemically administered pulmonary vasodilators, careful monitoring for hypotension and worsening hypoxemia is imperative.
We sought to investigate the hypothesis that premature birth may be associated with pulmonary vein stenosis (PVS). We undertook a retrospective multicenter cohort study of patients born prematurely and diagnosed with PVS between 2000 and 2014. We excluded total anomalous pulmonary venous drainage, heterotaxy, or gestational age ≥ 37 weeks. We identified 39 patients: 67% were male, median gestational age was 28 weeks (range: 22-36 weeks), and mean birth weight was 1.1 kg (433-2,645 g). Fifteen patients (38%) were one of twins whose twin siblings were unaffected. At diagnosis, 72% had developed chronic lung disease (CLD) and 51% were discharged on home oxygen. History of PDA ligation was present in 31% of patients and necrotizing enterocolitis in 23%. Eighty-two percent of patients underwent echocardiography in the neonatal period without diagnosis of PVS. Median age at PVS diagnosis was 6.5 months (1 month-6 years). Evaluation for pulmonary hypertension in 67% of patients led to a diagnosis of PVS. In 23% of patients, PVS was found incidentally. PVS was diagnosed by echocardiography in 56% of patients and by contrast CT-angiography, MRI, or cardiac catheterization in 44%. Unilateral PVS was found in 64% of patients, and 88% of these had a left-side involvement. Management included surgery in 46%, supportive therapies in 44%, and a palliative approach in 10% of patients. Freedom from death or restenosis for all patients was 73% at 1 year and 55% at 2, 5, and 10 years. PVS diagnosed before 6 months was associated with shorter survival. In conclusion, PVS in infants who were born prematurely may be unapparent at birth, associated with pulmonary hypertension, CLD, and O 2 dependency, and often overlooked by routine echocardiogram. There is a male predisposition and a predilection for left-sided veins. The occurrence of PVS in one twin suggests that epigenetic factors may be important in the postnatal development or worsening of PVS.
Incidence of prematurity in a cohort of adult patients with pulmonary hypertension Conference and asked to complete a brief survey regarding their personal history of preterm birth. For the IU cohort, baseline characteristics, including demographics, classification of PH, hemodynamics, and functional status, were obtained from their medical records. A total of 225 patients were surveyed (n = 166 from IU and n = 59 from the PHA conference). When asked if born 4 or more weeks premature, 80.8% responded "no" (n = 80), 10.1% responded "unsure" (n = 10), and 9.1% responded "yes" (n = 9). Selfreported gestational age at birth was 32-36 weeks in preterm subjects (mean: 33.9 weeks). Distribution of WHO PH groups was similar among those with and without a history of prematurity, with group I PH accounting for 83% of term subjects and 77.8% of preterm subjects. In the IU cohort, baseline hemodynamics by right heart catheterization, functional status, 6-minute walk distance, and brain natriuretic peptide levels were similar between term-and preterm-born adults. In conclusion, in this medium-sized cohort of PH patients, a history of mild prematurity was encountered at a rate similar to that in the general population, suggesting that mild prematurity does not predispose to PH development later in life. Additional prospective studies are needed to determine the long-term risk for developing PH in adults with a history of moderate or severe prematurity. MicroRNAs (miR/miRNA) are small, noncoding, single-stranded RNAs that pair with mRNA to negatively regulate gene expression through degradation or suppression of translation. The role of miRNA in cardiovascular disease is increasingly appreciated, including cardiac development, remodeling, and hypertrophy and heart failure. In our ovine model of congenital heart disease with a fetally implanted aortopulmonary shunt and increased pulmonary blood flow, we have demonstrated a novel adaptive right ventricular (RV) response to increased afterload, along with global cardiac hypertrophy, which may be due to preservation of the fetal phenotype. We hypothesized that shunt RV would have an miRNA expression pattern distinct from control but similar to fetal RV and that miRNA gene regulation contributes to the adaptive shunt RV phenotype. Late-gestation fetal lambs (n = 5) underwent placement of an aortopulmonary vascular graft (shunt). Four weeks after delivery, RV tissue was harvested from shunt and twin controls. Fetal RV tissue was obtained from late-gestation lambs. The miRNA expression levels were determined by quantitative PCR, and screening for downstream targets used RNA sequencing (n = 3 for RNA seq.). Of the 93 miRNA targets analyzed in control, shunt, and fetal RV tissue, 57 miRs were significantly different from control in either shunt or fetal RV or both. Of these 57, 14 targets were similarly up-or downregulated in shunt and fetal RV, compared to control. Eleven were upregulated in both: miRs 18a-5p, 25-3p, 30a-5p, 99b-5p, 106b-5p, 127-3p, 210-3p, 379-5p, 382-5p, 543, and 664-3p . Three were downregulated in both: miRs 199b-5p, 208a-3p, and 378a-3p. For these 14 miRs, we then utilized RNA sequencing as a screen for known downstream targets of miR regulation. There were significant changes in mRNA targets of miR 18a-5p, 25-3p, 30a-5p, 106b-5p, 210-3p, 199b-5p, 208a-3p, and 378a-3p in shunt RV, compared to control. Further, these downstream genes are potentially involved in adaptive hypertrophy mechanisms, as they target physiologic hypertrophy, angiogenesis, cardiac fibrosis, and ROS scavenging. In conclusion, the molecular and biochemical mechanisms underlying adaptive RV hypertrophy, as distinct from pathologic hypertrophy and failure, are incompletely elucidated. These preliminary data suggest that miRNA expression patterns in the RV of fetal and shunt lambs may confer an adaptive phenotype through downstream gene regulation. If validated, pharmacologic targeting of miRNA is a tantalizing potential target for therapeutic intervention in congenital heart disease and pulmonary hypertension.
Increased reliance on right atrial active emptying at diagnosis is associated with clinical worsening in children with pulmonary arterial hypertension. 
